


Claims:

1. A compound of formula (I):



(I)

wherein:

R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_{2-4} alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional substitutions are made with 0, 1, 2 or 3 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^c;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C_{1-6} alkyl, or C_{1-6} alkoxy;

R², R³, R⁶ and R⁷ are independently selected from H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted C_{1-6} alkyl, or optionally substituted C_{3-6} cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e

moieties, with the requirement that one or more of R^2 , R^3 , R^6 and R^7 are aromatic or heteroaromatic;

R^4 is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $CR^9R^{10}R^{11}$;

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} or $CH(OH)R^{13}$;

R^9 , R^{10} and R^{11} are, at each occurrence independently selected from H, F, C_{1-4} alkyl, OH, OCH_3 , SH, SCH_3 , CH_2SCH_3 ;

R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^{13} is C_{1-6} alkyl or R^{12} ;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1, wherein:

R^1 is selected from H, or optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from C_{1-6} cycloalkyl, C_{1-6} cycloalkoxy, or phenyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R^2 , R^3 , R^6 and R^7 are aromatic;

R^4 is H, or C_{1-6} alkyl;

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} ;

R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO_2 , CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy; or a pharmaceutically acceptable salt thereof.

3. A compound of claim 1, wherein:

R^1 is selected from H, $-C_{1-6}$ alkyl, $-(CH_2)_2OCH_3$, $-CH_2$ -phenyl, $-CH_2C_{1-6}$ cycloalkyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH_3 ;

R^4 is H, or C_{1-6} alkyl;

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 ; or a pharmaceutically acceptable salt thereof.

5 4. A compound of claim 1, wherein:

R^1 is $-C_{1-3}$ alkyl, $-CH_2C_{1-4}$ cycloalkyl.

5. A compound of claim 1, wherein:

R^1 is methyl or $-CH_2$ cyclopropane.

6. A compound of claim 1, wherein:

10 R^e is, at each occurrence independently selected from F, Cl, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy.

7. A compound of claim 1, wherein:

R^2 is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.

15 8. A compound of claim 1, wherein:

R^3 , R^6 and R^7 are H.

9. A compound of claim 1, wherein:

R^4 is C_{1-6} alkyl.

10. A compound of claim 1, wherein:

20 R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 .

11. A compound of formula (I) selected from:

25 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*R*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

30 N^1 -[(3*S*,7*R*)-1-(cyclopropylmethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1 -[(3*S*,7*S*)-1-benzyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;

- N^1 -[(3*S*,7*R*)-1-benzyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*S*)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3*S*,7*R*)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;
- N^2 -[(2*S*)-2-hydroxy-4-methylpentanoyl]- N^1 -[(3*S*,7*S*)-1-(2-methoxyethyl)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-leucinamide;
- N^1 -[(3*R*,7*S*)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -
- 10 [(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^1 -[(3*S*,7*S*)-1-cyclopentyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^1 -[(3*R*,7*S*)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- 15 N^1 -[(3*S*,7*S*)-1-isobutyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- N^1 -[(3*R*,7*S*)-1-(cyclopropylmethyl)-7-(4-fluorophenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-
- 20 azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide
- N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide (11)
- N^1 -[(3*R*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(3,5-difluorophenyl)acetyl]-L-alaninamide;
- 25 N^1 -[(3*S*,7*S*)-1-(cyclopropylmethyl)-7-(4-methoxyphenyl)-2-oxo-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]- N^2 -[(2*S*)-2-hydroxy-4-methylpentanoyl]-L-leucinamide;
- N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-1-methyl-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;
- N^2 -[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3*S*,7*S*)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1*H*-azepin-3-yl]-L-alaninamide;

- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-6-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-5,7-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;


N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

- 5 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4,6-diphenyl-2,3,4,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide.

10

12. A compound of formula (II):



(II)

15

wherein:

R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_{2-4} alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional
20 substitutions are made with 0, 1, 2 or 3 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^c;

- 25 R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b ;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO_2 , CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy;

5 R^2 , R^3 , R^6 and R^7 are independently selected from H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted C_{1-6} alkyl, or optionally substituted C_{3-6} cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e
10 moieties, with the requirement that one or more of R^2 , R^3 , R^6 and R^7 are aromatic or heteroaromatic;

R^4 is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2
15 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $CR^9R^{10}R^{11}$;

R^5 is C_{1-3} alkyl R^{12} or $CH(OH)R^{13}$;

R^9 , R^{10} and R^{11} are, at each occurrence independently selected from H, F, C_{1-4} alkyl, OH, OCH_3 , SH, SCH_3 , CH_2SCH_3 ;

20 R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^{13} is C_{1-6} alkyl or R^{12} ;

or a pharmaceutically acceptable salt thereof.

13. A compound of formula (II), wherein:

25 R^1 is selected from H, or optionally substituted alkyl wherein such optional substitution is made with 0, 1, or 2 substituents selected from C_{1-6} cycloalkyl, C_{1-6} cycloalkoxy, or phenyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e
30 moieties, with the requirement that one or more of R^2 , R^3 , R^6 and R^7 are aromatic;

R^4 is H, or C_{1-6} alkyl;

R^5 is C_{1-3} alkyl R^{12} or C_{1-6} alkyl;

R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO_2 , CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy; or a pharmaceutically acceptable salt thereof.

5 14. A compound of claim 12, wherein:

R^1 is selected from H, -C_{1-6} alkyl, $\text{-(CH}_2)_2\text{OCH}_3$, $\text{-CH}_2\text{-phenyl}$, $\text{-CH}_2\text{C}_{1-6}$ cycloalkyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or OCH_3 ;

R^4 is H, or C_{1-6} alkyl;

R^5 is -C_{1-6} alkyl, -C_{1-3} alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 ; or a pharmaceutically acceptable salt thereof.

15 15. A compound of claim 12, wherein:

R^1 is selected from -C_{1-3} alkyl, or $\text{-CH}_2\text{C}_{1-4}$ cycloalkyl.

16. A compound of claim 12, wherein:

R^1 is selected from methyl or $\text{-CH}_2\text{cyclopropane}$.

17. A compound of claim 12, wherein:

20 R^e is at each occurrence independently selected from F, Cl, CF_3 , C_{1-6} alkyl, or C_{1-6} alkoxy.

18. A compound of claim 12, wherein:

R^2 is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.

25 19. A compound of claim 12, wherein:

R^3 , R^6 and R^7 are H.

20. A compound of claim 12, wherein:

R^4 is C_{1-6} alkyl.

21. A compound of claim 12, wherein:

30 R^5 is -C_{1-6} alkyl, -C_{1-3} alkyl R^{12} wherein R^{12} is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 .

22. A compound of formula (II) selected from:

- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-7-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 15 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 20 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-5-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;
- 30 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;


N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-1-methyl-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide;

N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S)-2-oxo-4-phenyl-2,3,6,7-tetrahydro-1H-azepin-3-yl]-L-alaninamide.

10 23. A compound of formula (III):



(III)

wherein:

15 R^1 is selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted alkyl, optionally substituted C_{3-6} cycloalkyl, C_{2-4} alkylNR^aR^b, or C_{1-4} alkylCOR^d, wherein all such optional substitutions are made with 0, 1, 2 or 3 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4} alkyl or C_{5-6} cycloalkyl, or R^a and R^b and the N to which they are attached in combination form
20 a 5 or 6-membered N-linked heterocycle having 2 nitrogen or, 1 nitrogen and 1 oxygen, ring atoms, wherein the non-linked nitrogen is substituted with R^c;

R^c is, at each occurrence independently selected from H, C_{1-3} alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

25 R^d is, at each occurrence independently selected from C_{1-3} alkyl, C_{1-3} alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C_{1-6} alkyl, or C_{1-6} alkoxy;

R^2 , R^3 and R^7 are independently selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, optionally substituted C_{1-6} alkyl, or optionally substituted C_{3-6} cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R^2 , R^3 and R^7 are aromatic or heteroaromatic;

R^6 is independently selected from H, optionally substituted C_{1-3} alkylaryl, optionally substituted C_{1-3} alkylheterocycle, optionally substituted C_{1-6} alkyl, or optionally substituted C_{3-6} cycloalkyl, wherein all such optional substitutions are made with 0, 1, 2, or 3 R^e moieties;

R^4 is H, optionally substituted 5- or 6-membered aromatic or heteroaromatic ring, said ring having 0,1,2 or 3, nitrogen, oxygen or sulfur atoms, but not more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom, C_{1-6} alkyl, C_{3-6} cycloalkyl, or $CR^9R^{10}R^{11}$;

R^5 is $-C_{1-6}$ alkyl, $-C_{1-3}$ alkyl R^{12} or $CH(OH)R^{13}$;

R^9 , R^{10} and R^{11} are, at each occurrence independently selected from H, F, C_{1-4} alkyl, OH, OCH_3 , SH, SCH_3 , CH_2SCH_3 ;

R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^{13} is C_{1-6} alkyl or R^{12} ;

or a pharmaceutically acceptable salt thereof.

24. A compound of formula (III), wherein:

R^1 is selected from H, or optionally substituted alkyl, wherein such optional substitution is made with 0, 1, or 2 substituents selected from C_{1-6} cycloalkyl, C_{1-6} cycloalkoxy, or phenyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or optionally substituted 6-membered aromatic, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties, with the requirement that one or more of R^2 , R^3 , R^6 and R^7 are aromatic;

R^4 is H, or C_{1-6} alkyl;

R^5 is $-C_{1-6}$ alkyl or $-C_{1-3}$ alkyl R^{12} ;

R^{12} is phenyl substituted with 0, 1, 2 or 3 R^e ;

R^e is, at each occurrence independently selected from OH, F, Cl, Br, I, CN, NO₂, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy; or a pharmaceutically acceptable salt thereof.

5 25. A compound of formula (III), wherein:

R^1 is selected from H, -C₁₋₆alkyl, -(CH₂)₂OCH₃, -CH₂-phenyl, -CH₂C₁₋₆cycloalkyl;

R^2 , R^3 , R^6 and R^7 are independently selected from H, or a substituted phenyl, wherein such substituent is selected from 1, 2, or 3 of the following F, Cl, Br, I or

10 OCH₃;

R^4 is H, or C₁₋₆alkyl;

R^5 is -C₁₋₆alkyl, -C₁₋₃alkylR¹² wherein R¹² is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH₃; or a pharmaceutically acceptable salt thereof.

15

26. A compound of claim 23, wherein:

R^1 is -C₁₋₆alkyl, -CH₂C₁₋₄cycloalkyl.

27. A compound of claim 23, wherein:

20 R^1 is methyl or -CH₂cyclopropane.

28. A compound of claim 23, wherein:

R^e is, at each occurrence independently selected from F, Cl, CF₃, C₁₋₆alkyl, or C₁₋₆alkoxy.

25 29. A compound of claim 23, wherein:

R^2 is an optionally substituted phenyl, wherein such optional substitution is made with 0, 1, 2, or 3 R^e moieties.

30. A compound of claim 23, wherein:

R^3 , R^6 and R^7 are H.

30 31. A compound of claim 23, wherein:

R^4 is C₁₋₆alkyl.

32. A compound of claim 23, wherein:

R^5 is $-C_{1-6}alkyl$, $-C_{1-3}alkylR^{12}$ wherein R^{12} is a substituted phenyl, wherein such substituent is selected from 1, 2 or 3 of the following F, Cl, Br, I or OCH_3 .

33. A compound of formula (III) selected from:

- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3R,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-
- 10 alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3R,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide (3□);
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7R)-2-oxo-7-phenylazepan-3-yl]-L-
- alaninamide;
- 15 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-
- 20 phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7R)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,7S)-2-oxo-7-phenylazepan-3-yl]-L-
- alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-1-methyl-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-
- 30 phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,7S)-2-oxo-7-phenylazepan-3-yl]-L-alaninamide;

- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6R)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-1-methyl-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- 20 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,6S)-2-oxo-6-phenylazepan-3-yl]-L-alaninamide;
- 25 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- 30 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;

- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-1-methyl-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S)-2-oxo-4-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 20 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 30 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;

- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,7S)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 10 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-1-methyl-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,7R)-2-oxo-4,7-diphenylazepan-3-yl]-L-alaninamide;
- 20 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- 30 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;

- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-
- 10 diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4S,6S)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-1-methyl-2-oxo-
- 20 4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,4R,6R)-2-oxo-4,6-diphenylazepan-3-yl]-L-alaninamide;
- 25 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-
- 30 5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;

- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- 10 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S,7S)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- 20 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-1-methyl-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- 25 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R,7R)-2-oxo-5,7-diphenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- 30 N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;

- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- 5 N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5S)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-
- 10 L-alaninamide;
- N^2 -[(3,5-difluorophenyl)acetyl]- N^1 -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- 15 N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-1-methyl-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-2-oxo-5-phenylazepan-3-yl]-L-alaninamide;
- N^2 -[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]- N^1 -[(3S,5R)-2-oxo-5-
- 20 phenylazepan-3-yl]-L-alaninamide.

34. A compound according to any one of claims 1 to 33, for use as a medicament.

35. A compound as defined in any one of claims 1 to 33 for the use in the treatment of neurological disorders.

- 25 36. A compound as defined in any one of claims 1 to 33 for the use in the prevention of Alzheimer's disease, or Down's Syndrome.

37. A compound as defined in any one of claims 1 to 33 for the use in the treatment of Alzheimer's disease, or Down's Syndrome.

38. The use of a compound as defined in any one of claims 1 to 33, in the
- 30 manufacture of a medicament for the treatment or prophylaxis of disorders associated with β -amyloid production.

39. A method of treatment of a human or animal suffering from neurological disorders associated with β -amyloid production comprising administering to a host in

need of such treatment a therapeutically effective amount of a compound as defined in any one of claims 1 to 33.

40. A method of treating Alzheimer's disease in a patient comprising administering to a patient in need of such treatment an effective amount of a compound as defined in
5 any one of claims 1 to 33.

41. A method of treating dementia in a patient comprising administering to a patient in need of such treatment and effective amount of a compound as defined in any one of claims 1 to 33.

42. A method of treating age associated cognitive decline, mild cognitive
10 impairment, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's Syndrome in a patient comprising administering to a patient in need of such treatment and effective amount of a compound as defined in any one of claims 1 to 33.

43. A method of preventing Alzheimer's disease a patient comprising administering
15 to a patient at risk of developing Alzheimer's disease an effective amount of a compound as defined in any one of claims 1 to 33.


44. A method of preventing dementia in a patient comprising administering to a patient at risk of developing dementia an effective amount of a compound as defined in any one of claims 1 to 33.

20 45. A method of preventing age associated cognitive decline, mild cognitive impairment, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's Syndrome in a patient comprising administering to a patient at risk of developing a learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder or Down's
25 Syndrome an effective amount of a compound as defined in any one of claims 1 to 33.


46. A method for inhibiting γ -secretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound as defined in any one of claims 1 to 33.

30 47. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 33 or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.


48. A process for preparing a compound of formula 1f comprising reacting a compound of formula 1d with TFA.




49. A process for preparing a compound of formula 1 comprising reacting a
5 compound of formula 1f and *N*-[(3,5-difluorophenyl)acetyl]-*L*-alanine with HOBt-hydrate, EDAC.HCL and *N*-methyl morpholine.




50. A process for preparing a compound of formula 2e comprising reacting a compound of formula 2c with H₂, Pearlman's Catalyst in ETOH.




51. A process for preparing a compound of formula 2 comprising reacting a compound of formula 2e and *N*-[(3,5-difluorophenyl)acetyl]-*L*-alanine with HOBt-hydrate, EDAC.HCL and *N*-methyl morpholine.



52. A process for preparing a compound of formula 11f comprising reacting a compound of formula 11d with H_2NNH_2 in MeOH.

**11d**

5 53. A process for preparing a compound of formula 11A comprising reacting a compound of formula 11f and *N*-[(3,5-difluorophenyl)acetyl]-L-alanine with with HOBt-hydrate, EDAC.HCL and *N*-methyl morpholine.

**11A**